Released Nov 9, 2026, before the open
10-Q filed Nov 9, 2026, 40 days after period end · 0001628280-26-072178
In October 2026, the Company announced a comprehensive strategic financial restructuring that included an $86.6 million private investment in public equity (PIPE) financing with participation from new investor Bain Capital Life Sciences and existing investors Redmile, TCGX, and Nantahala Capital.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $21.01M | $15.75M | $18.02M | $14.27M |
| Net Income | -$25.30M | -$40.97M |
ADC Therapeutics SA · CIK 1771910 · Engraved from SEC EDGAR
| -$43.97M |
| -$46.73M |
| EPS Diluted | -$0.16 | -$0.30 | -$0.42 | -$0.57 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ADC Therapeutics reported net product revenues of $21.0 million for the third quarter and $59.7 million for the nine months ended September 30, 2026, compared with $15.8 million and $51.2 million in the same periods of 2025.¶2
In October 2026 the company announced an $86.6 million PIPE financing and amendments eliminating a $150 million change-of-control payment and reducing senior secured loan principal by $68.5 million to $50 million.¶1
Total operating expenses were $36.1 million for the third quarter and $126.8 million for the nine months ended September 30, 2026, compared with $47.4 million and $161.9 million, a reduction of 24% and 22%.¶3
Net loss was $25.3 million, or $0.16 per basic and diluted share, for the third quarter, compared with $41.0 million, or $0.30 per share, for the same period in 2025.¶4
Cash and cash equivalents were $189.2 million as of September 30, 2026, compared with $261.3 million as of December 31, 2025, and the company expects its cash runway to extend into 2029.¶5¶6